{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:23Z","timestamp":1791357383176,"version":"4.3.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11920-025-01606-8","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:44:59Z","timestamp":1743342299000},"page":"239-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-0825","authenticated-orcid":false,"given":"Anastasia K.","family":"Yocum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7062-8192","authenticated-orcid":false,"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"1606_CR1","doi-asserted-by":"publisher","unstructured":"Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, \u2026 Grande I. Bipolar disorders. Nat Rev Dis Primers. 2018;4(1):18008. https:\/\/doi.org\/10.1038\/nrdp.2018.8.","DOI":"10.1038\/nrdp.2018.8"},{"key":"1606_CR2","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796021000305","author":"JKN Chan","year":"2021","unstructured":"Chan JKN, Wong CSM, Yung NCL, Chen EYH, Chang WC. Excess mortality and life-years lost in people with bipolar disorder: an 11-year population-based cohort study. Epidemiol Psychiatr Sci. 2021. https:\/\/doi.org\/10.1017\/S2045796021000305.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"1606_CR3","doi-asserted-by":"publisher","unstructured":"Burdick KE, Millett CE, Yocum AK, Altimus CM, Andreassen OA, Aubin V, \u2026 McInnis MG. Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disord. 2022;24(7):709\u2013719. https:\/\/doi.org\/10.1111\/bdi.13208.","DOI":"10.1111\/bdi.13208"},{"key":"1606_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2017.09.011","volume":"226","author":"M Cloutier","year":"2018","unstructured":"Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45\u201351. https:\/\/doi.org\/10.1016\/j.jad.2017.09.011.","journal-title":"J Affect Disord"},{"key":"1606_CR5","doi-asserted-by":"publisher","unstructured":"Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Nomura I, \u2026 Iwata N. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27(2):1136\u20131144. https:\/\/doi.org\/10.1038\/s41380-021-01334-4.","DOI":"10.1038\/s41380-021-01334-4"},{"key":"1606_CR6","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.2147\/NDT.S273503","volume":"18","author":"OH Elsayed","year":"2022","unstructured":"Elsayed OH, Ercis M, Pahwa M, Singh B. Treatment-resistant bipolar depression: therapeutic trends, challenges and future directions. Neuropsychiatr Dis Treat. 2022;18:2927\u201343. https:\/\/doi.org\/10.2147\/NDT.S273503.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1606_CR7","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Berk M, Brietzke E, Goldstein BI, L\u00f3pez-Jaramillo C, Kessing LV, \u2026 Mansur RB. Bipolar disorders. Lancet. 2020;396(10265):1841\u20131856. https:\/\/doi.org\/10.1016\/S0140-6736(20)31544-0.","DOI":"10.1016\/S0140-6736(20)31544-0"},{"issue":"1","key":"1606_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"AF Carvalho","year":"2020","unstructured":"Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383(1):58\u201366. https:\/\/doi.org\/10.1056\/NEJMra1906193.","journal-title":"N Engl J Med"},{"key":"1606_CR9","doi-asserted-by":"publisher","unstructured":"Wright K, Koenders M, Douglas KM, Faurholt\u2010Jepsen M, Lewandowski KE, Miklowitz DJ, \u2026 Mesman E. Psychological therapies for people with bipolar disorder: where are we now, and what is next? ISBD psychological interventions taskforce\u2014position paper. Bipolar Disorders. 2024;bdi.13418. https:\/\/doi.org\/10.1111\/bdi.13418.","DOI":"10.1111\/bdi.13418"},{"key":"1606_CR10","doi-asserted-by":"publisher","unstructured":"Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, \u2026 Murray G. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatr. 2021;55(1):7\u2013117. https:\/\/doi.org\/10.1177\/0004867420979353.","DOI":"10.1177\/0004867420979353"},{"key":"1606_CR11","doi-asserted-by":"publisher","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, \u2026 Berk M. Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609.","DOI":"10.1111\/bdi.12609"},{"key":"1606_CR12","doi-asserted-by":"publisher","unstructured":"Fiorillo A, Sampogna G, Albert U, Maina G, Perugi G, Pompili M, \u2026 Tortorella A. Facts and myths about the use of lithium for bipolar disorder in routine clinical practice: an expert consensus paper. Ann Gen Psychiatry. 2023;22(1):50. https:\/\/doi.org\/10.1186\/s12991-023-00481-y.","DOI":"10.1186\/s12991-023-00481-y"},{"key":"1606_CR13","doi-asserted-by":"publisher","unstructured":"Katz IR, Rogers MP, Lew R, Thwin SS, Doros G, Ahearn E, \u2026 Yurgelun-Todd D. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(1):24. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.3170.","DOI":"10.1001\/jamapsychiatry.2021.3170"},{"key":"1606_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euroneuro.2021.10.003","volume":"54","author":"KN Fountoulakis","year":"2022","unstructured":"Fountoulakis KN, Tohen M, Zarate CA. Lithium treatment of bipolar disorder in adults: a systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol. 2022;54:100\u201315. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.10.003.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"1606_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1192\/bjp.2023.75","volume":"223","author":"M L\u00e4hteenvuo","year":"2023","unstructured":"L\u00e4hteenvuo M, Palj\u00e4rvi T, Tanskanen A, Taipale H, Tiihonen J. Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study. Br J Psychiatry. 2023;223(4):456\u201364. https:\/\/doi.org\/10.1192\/bjp.2023.75.","journal-title":"Br J Psychiatry"},{"key":"1606_CR16","doi-asserted-by":"publisher","unstructured":"Burdick KE, Millett CE, Russo M, Alda M, Alliey-Rodriguez N, Anand A, \u2026 Kelsoe JR. The association between lithium use and neurocognitive performance in patients with bipolar disorder. Neuropsychopharmacology. 2020;45(10), 1743\u20131749. https:\/\/doi.org\/10.1038\/s41386-020-0683-2.","DOI":"10.1038\/s41386-020-0683-2"},{"issue":"5","key":"1606_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","volume":"215","author":"OV Forlenza","year":"2019","unstructured":"Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019;215(5):668\u201374. https:\/\/doi.org\/10.1192\/bjp.2019.76.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1606_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bdi.13209","volume":"24","author":"M Pahwa","year":"2022","unstructured":"Pahwa M, Singh B. Lithium in patients with chronic kidney disease \u2013 To continue versus discontinue? Bipolar Disord. 2022;24(5):549\u201350. https:\/\/doi.org\/10.1111\/bdi.13209.","journal-title":"Bipolar Disord"},{"issue":"1","key":"1606_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40345-024-00351-w","volume":"12","author":"FN Adiukwu","year":"2024","unstructured":"Adiukwu FN, Yocum AK, Wright BM, Gesler I, McInnis MG. Lithium in the time of COVID: forever vigilant. Int J Bipolar Disord. 2024;12(1):29. https:\/\/doi.org\/10.1186\/s40345-024-00351-w.","journal-title":"Int J Bipolar Disord"},{"issue":"5","key":"1606_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/JCP.0000000000001586","volume":"42","author":"MG McInnis","year":"2022","unstructured":"McInnis MG, Yocum AK. Case reports: exposure to SARS-CoV-2, acute kidney injury, and lithium toxicity. J Clin Psychopharmacol. 2022;42(5):461\u20133. https:\/\/doi.org\/10.1097\/JCP.0000000000001586.","journal-title":"J Clin Psychopharmacol"},{"key":"1606_CR21","doi-asserted-by":"publisher","unstructured":"Akinhanmi M, El-Amin S, Balls-Berry JE, Vallender EJ, Ladner M, Geske J, \u2026 Frye MA. Decreased core symptoms of mania and utilization of lithium\/mood stabilizing anticonvulsants in U.S. bipolar I patients of African vs European ancestry. J Affect Disorders. 2020;260:361\u2013365. https:\/\/doi.org\/10.1016\/j.jad.2019.09.022.","DOI":"10.1016\/j.jad.2019.09.022"},{"issue":"5","key":"1606_CR22","first-page":"22","volume":"49","author":"RG Clackler","year":"2024","unstructured":"Clackler RG, Felton KB, Holmes SA, Stabinsky HN, Yarbrough NB, Burmeister MA. Current and emerging therapies for bipolar disorder. US Pharm. 2024;49(5):22\u201334.","journal-title":"US Pharm."},{"key":"1606_CR23","doi-asserted-by":"publisher","unstructured":"Singh B, Yocum AK, Strawbridge R, Burdick KE, Millett CE, Peters AT, \u2026 The FACE-BD Collaborators, The Global Bipolar Cohort Collaborative. Patterns of pharmacotherapy for bipolar disorder: A GBC survey. Bipolar Disord. 2024;26(1):22\u201332. https:\/\/doi.org\/10.1111\/bdi.13366..","DOI":"10.1111\/bdi.13366."},{"issue":"8","key":"1606_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1176\/appi.ajp.2020.19091000","volume":"177","author":"TG Rhee","year":"2020","unstructured":"Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry. 2020;177(8):706\u201315. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19091000.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1606_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40345-023-00322-7","volume":"12","author":"LV Kessing","year":"2024","unstructured":"Kessing LV. Why is lithium [not] the drug of choice for bipolar disorder? a controversy between science and clinical practice. Int J Bipolar Disord. 2024;12(1):3. https:\/\/doi.org\/10.1186\/s40345-023-00322-7.","journal-title":"Int J Bipolar Disord"},{"issue":"1","key":"1606_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40345-020-00215-z","volume":"9","author":"X P\u00e9rez De Mendiola","year":"2021","unstructured":"P\u00e9rez De Mendiola X, Hidalgo-Mazzei D, Vieta E, Gonz\u00e1lez-Pinto A. Overview of lithium\u2019s use: a nationwide survey. Int J Bipolar Disord. 2021;9(1):10. https:\/\/doi.org\/10.1186\/s40345-020-00215-z.","journal-title":"Int J Bipolar Disord"},{"issue":"1","key":"1606_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/brainsci14010102","volume":"14","author":"YK Shuy","year":"2024","unstructured":"Shuy YK, Santharan S, Chew QH, Sim K. International trends in lithium use for pharmacotherapy and clinical correlates in bipolar disorder: a scoping review. Brain Sci. 2024;14(1): 102. https:\/\/doi.org\/10.3390\/brainsci14010102.","journal-title":"Brain Sci"},{"key":"1606_CR28","doi-asserted-by":"publisher","unstructured":"Carli M, Weiss F, Grenno G, Ponzini S, Kolachalam S, Vaglini F, \u2026 Scarselli M. (2023). Pharmacological Strategies for Bipolar Disorders in Acute Phases andChronic Management with a Special Focus on Lithium, Valproic Acid, andAtypical Antipsychotics. Curr Neuropharmacol. 2023;21(4):935\u2013950. https:\/\/doi.org\/10.2174\/1570159X21666230224102318.","DOI":"10.2174\/1570159X21666230224102318"},{"issue":"3","key":"1606_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.9758\/cpn.2022.20.3.403","volume":"20","author":"C Crapanzano","year":"2022","unstructured":"Crapanzano C, Casolaro I, Amendola C, Damiani S. Lithium and valproate in bipolar disorder: from international evidence-based guidelines to clinical predictors. Clin Psychopharmacol Neurosci. 2022;20(3):403\u201314. https:\/\/doi.org\/10.9758\/cpn.2022.20.3.403.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"5","key":"1606_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/medicina57050433","volume":"57","author":"A Grunze","year":"2021","unstructured":"Grunze A, Amann BL, Grunze H. Efficacy of carbamazepine and its derivatives in the treatment of bipolar disorder. Medicina. 2021;57(5): 433. https:\/\/doi.org\/10.3390\/medicina57050433.","journal-title":"Medicina"},{"key":"1606_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2147\/NDT.S245166","volume":"16","author":"N Yalin","year":"2020","unstructured":"Yalin N, Young AH. Pharmacological treatment of bipolar depression: what are the current and emerging options? Neuropsychiatr Dis Treat. 2020;16:1459\u201372. https:\/\/doi.org\/10.2147\/NDT.S245166.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"1606_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/pgs-2023-0054","volume":"24","author":"Q Meng","year":"2023","unstructured":"Meng Q, Gu H, Zhang Q, Yi Z, Jiang D. Carbamazepine cutaneous adverse reactions and HLA gene variation in the Chinese population: a systematic review and meta-analysis. Pharmacogenomics. 2023;24(8):459\u201374. https:\/\/doi.org\/10.2217\/pgs-2023-0054.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"1606_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/JCP.0000000000001475","volume":"41","author":"R Kumar","year":"2021","unstructured":"Kumar R, Nu\u00f1ez NA, Prokop LJ, Veldic M, Betcher H, Singh B. Association of optimal lamotrigine serum levels and therapeutic efficacy in mood disorders: a systematic review. J Clin Psychopharmacol. 2021;41(6):681\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000001475.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1606_CR34","first-page":"118","volume":"50","author":"M Pahwa","year":"2020","unstructured":"Pahwa M, Nu\u00f1ez NA, Joseph B, Seshadri A, Gerberi DJ, Frye MA, Singh B. Efficacy and tolerability of lamotrigine in borderline personality disorder: a systematic review and meta-analysi. Psychopharmacol Bull. 2020;50(4):118\u201336.","journal-title":"Psychopharmacol Bull"},{"key":"1606_CR35","doi-asserted-by":"publisher","unstructured":"Ketter et al. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar i disorder: a randomized trial. 2006.https:\/\/doi.org\/10.4088\/jcp.v67n0310.","DOI":"10.4088\/jcp.v67n0310"},{"issue":"4","key":"1606_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/JCP.0000000000001557","volume":"42","author":"T Nakamura","year":"2022","unstructured":"Nakamura T, Tomita M, Hirota S, Matsunaga T, Uchimura N. Impact of selected initial titration schedules on safety and long-term effectiveness of lamotrigine for the treatment of mood disorders. J Clin Psychopharmacol. 2022;42(4):350\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000001557.","journal-title":"J Clin Psychopharmacol"},{"key":"1606_CR37","doi-asserted-by":"publisher","unstructured":"Lin S-K, Yang S-Y, Park S-C, Jang O-J, Zhu X, Xiang Y-T, \u2026 Shinfuku N. Prescription patterns for bipolar disorder in Asian countries: findings from research on Asian prescription pattern-bipolar disorder. Clin Psychopharmacol Neurosci. 2022;20(1):61\u201369. https:\/\/doi.org\/10.9758\/cpn.2022.20.1.61.","DOI":"10.9758\/cpn.2022.20.1.61"},{"issue":"7","key":"1606_CR38","doi-asserted-by":"publisher","first-page":"JC82","DOI":"10.7326\/ANNALS-24-00855-JC","volume":"177","author":"B Singh","year":"2024","unstructured":"Singh B. In women with epilepsy, use of valproate in the second half of pregnancy was linked to autism in offspring. Annals of Internal Medicine. 2024;177(7):JC82. https:\/\/doi.org\/10.7326\/ANNALS-24-00855-JC.","journal-title":"Annals of Internal Medicine"},{"key":"1606_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euroneuro.2022.12.012","volume":"68","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Durgam S, Kozauer SG, Chen R, Huo J, Davis RE, Cutler AJ. The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: secondary and post hoc analyses. Eur Neuropsychopharmacol. 2023;68:78\u201388. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.12.012.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"1606_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12325-022-02350-8","volume":"40","author":"L Citrome","year":"2023","unstructured":"Citrome L, Risinger R, Rajachandran L, Robison H. Correction to: sublingual dexmedetomidine for agitation associated with schizophrenia or bipolar disorder: a post hoc analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Adv Ther. 2023;40(1):391\u2013391. https:\/\/doi.org\/10.1007\/s12325-022-02350-8.","journal-title":"Adv Ther"},{"issue":"5","key":"1606_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/87551225221114281","volume":"38","author":"H Pham","year":"2022","unstructured":"Pham H, Warlick H, Bermudez R, Nguyen Q, Rey JA. Olanzapine\/samidorphan: a new option for the treatment of adults with schizophrenia or bipolar I disorder. J Pharm Technol. 2022;38(5):304\u201313. https:\/\/doi.org\/10.1177\/87551225221114281.","journal-title":"J Pharm Technol"},{"key":"1606_CR42","doi-asserted-by":"publisher","unstructured":"Fornaro M, De Berardis D, Perna G, Solmi M, Veronese N, Orsolini L, \u2026 De Bartolomeis A. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Res Int. 2017;1\u201317. https:\/\/doi.org\/10.1155\/2017\/3084859.","DOI":"10.1155\/2017\/3084859"},{"issue":"1","key":"1606_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40345-017-0075-7","volume":"5","author":"A Pikalov","year":"2017","unstructured":"Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A. Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. Int J Bipolar Disord. 2017;5(1):9. https:\/\/doi.org\/10.1186\/s40345-017-0075-7.","journal-title":"Int J Bipolar Disord"},{"issue":"3","key":"1606_CR44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/brainsci13030414","volume":"13","author":"JK Rybakowski","year":"2023","unstructured":"Rybakowski JK. Application of antipsychotic drugs in mood disorders. Brain Sci. 2023;13(3): 414. https:\/\/doi.org\/10.3390\/brainsci13030414.","journal-title":"Brain Sci"},{"issue":"4","key":"1606_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bdi.12852","volume":"22","author":"WR Earley","year":"2020","unstructured":"Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020;22(4):372\u201384. https:\/\/doi.org\/10.1111\/bdi.12852.","journal-title":"Bipolar Disord"},{"key":"1606_CR46","doi-asserted-by":"publisher","unstructured":"Earley W, Burgess MV, Rekeda L, Dickinson R, Szatm\u00e1ri B, N\u00e9meth G, \u2026 Yatham LN. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry. 2019;176(6), 439\u2013448. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18070824.","DOI":"10.1176\/appi.ajp.2018.18070824"},{"key":"1606_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.769897","volume":"12","author":"A Do","year":"2021","unstructured":"Do A, Keramatian K, Schaffer A, Yatham L. Cariprazine in the treatment of bipolar disorder: within and beyond clinical trials. Front Psych. 2021;12: 769897. https:\/\/doi.org\/10.3389\/fpsyt.2021.769897.","journal-title":"Front Psych"},{"key":"1606_CR48","doi-asserted-by":"publisher","unstructured":"Straub L, Hern\u00e1ndez-D\u00edaz S, Bateman BT, Wisner KL, Gray KJ, Pennell PB, \u2026 Huybrechts KF. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. JAMA Intern Med. 2022;182(5):522. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0375.","DOI":"10.1001\/jamainternmed.2022.0375"},{"issue":"3","key":"1606_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41386-021-01223-y","volume":"47","author":"NC Momen","year":"2022","unstructured":"Momen NC, Robakis T, Liu X, Reichenberg A, Bergink V, Munk-Olsen T. In utero exposure to antipsychotic medication and psychiatric outcomes in the offspring. Neuropsychopharmacology. 2022;47(3):759\u201366. https:\/\/doi.org\/10.1038\/s41386-021-01223-y.","journal-title":"Neuropsychopharmacology"},{"key":"1606_CR50","doi-asserted-by":"publisher","unstructured":"Vidyasagaran AL, McDaid D, Faisal MR, Nasir M, Muliyala KP, Thekkumkara S, \u2026 Siddiqi N. Prevalence of mental disorders in South Asia: a systematic review of reviews. Cambridge Prisms Glob Ment Health. 2023;10:e78. https:\/\/doi.org\/10.1017\/gmh.2023.72.","DOI":"10.1017\/gmh.2023.72"},{"issue":"1","key":"1606_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41537-022-00276-2","volume":"8","author":"RC Zapata","year":"2022","unstructured":"Zapata RC, Silver A, Yoon D, Chaudry B, Libster A, McCarthy MJ, Osborn O. Antipsychotic-induced weight gain and metabolic effects show diurnal dependence and are reversible with time restricted feeding. Schizophrenia. 2022;8(1):70. https:\/\/doi.org\/10.1038\/s41537-022-00276-2.","journal-title":"Schizophrenia"},{"issue":"6","key":"1606_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.9740\/mhc.2021.11.311","volume":"11","author":"BM DeJongh","year":"2021","unstructured":"DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Mental Health Clin. 2021;11(6):311\u20139. https:\/\/doi.org\/10.9740\/mhc.2021.11.311.","journal-title":"Mental Health Clin"},{"key":"1606_CR53","unstructured":"Park JH, Nu\u00f1ez NA, Gardea-Resendez M, Gerberi DJ, Breitinger S, Veldic M, \u2026 Singh B. Short term second-generation antidepressant monotherapy in acute depressive episodes of bipolar ii disorder: a systematic review and meta-analysis. PsychoPharmacol Bull. 2022;52(2):45\u201372."},{"key":"1606_CR54","doi-asserted-by":"publisher","unstructured":"Frye MA, McElroy SL, Prieto ML, Harper KL, Walker DL, Kung S, \u2026 Biernacka JM. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. J Clin Psychiatry. 2015;76(02):174\u2013180. https:\/\/doi.org\/10.4088\/JCP.14m09127.","DOI":"10.4088\/JCP.14m09127"},{"key":"1606_CR55","doi-asserted-by":"publisher","unstructured":"Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, \u2026 Vieta E. The International Society for Bipolar Disorders (ISBD) Task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249\u20131262. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13020185.","DOI":"10.1176\/appi.ajp.2013.13020185"},{"issue":"1","key":"1606_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40345-018-0133-9","volume":"6","author":"MJ Gitlin","year":"2018","unstructured":"Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6(1):25. https:\/\/doi.org\/10.1186\/s40345-018-0133-9.","journal-title":"Int J Bipolar Disord"},{"key":"1606_CR57","doi-asserted-by":"publisher","unstructured":"Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin J-M, \u2026 on behalf of the Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19(1):2\u201358. https:\/\/doi.org\/10.1080\/15622975.2017.1384850.","DOI":"10.1080\/15622975.2017.1384850"},{"issue":"7","key":"1606_CR58","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1176\/appi.ajp.20240411","volume":"181","author":"N Gottlieb","year":"2024","unstructured":"Gottlieb N, Young AH. Antidepressants and bipolar disorder: the plot thickens. Am J Psychiatry. 2024;181(7):575\u20137. https:\/\/doi.org\/10.1176\/appi.ajp.20240411.","journal-title":"Am J Psychiatry"},{"key":"1606_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jad.2017.07.023","volume":"223","author":"B Liu","year":"2017","unstructured":"Liu B, Zhang Y, Fang H, Liu J, Liu T, Li L. Efficacy and safety of long-term antidepressant treatment for bipolar disorders \u2013 a meta-analysis of randomized controlled trials. J Affect Disord. 2017;223:41\u20138. https:\/\/doi.org\/10.1016\/j.jad.2017.07.023.","journal-title":"J Affect Disord"},{"key":"1606_CR60","doi-asserted-by":"publisher","unstructured":"Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, \u2026 Sachs GS. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar i or bipolar ii disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12), 1098\u20131106. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20091339.","DOI":"10.1176\/appi.ajp.2021.20091339"},{"issue":"5","key":"1606_CR61","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/JCP.0000000000001898","volume":"44","author":"B Singh","year":"2024","unstructured":"Singh B. Ketamine and esketamine for depression in daily practice. J Clin Psychopharmacol. 2024;44(5):451\u20135. https:\/\/doi.org\/10.1097\/JCP.0000000000001898.","journal-title":"J Clin Psychopharmacol."},{"issue":"6","key":"1606_CR62","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/14740338.2022.2045272","volume":"21","author":"B Singh","year":"2022","unstructured":"Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf. 2022;21(6):717\u201320. https:\/\/doi.org\/10.1080\/14740338.2022.2045272.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1606_CR63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bdi.13296","volume":"25","author":"Martinotti, G., Dell\u2019Osso, B., Di Lorenzo, G., Maina, G., Bertolino, A., Clerici, M., \u2026 the REAL-ESK Study Group","year":"2023","unstructured":"Martinotti, G., Dell\u2019Osso, B., Di Lorenzo, G., Maina, G., Bertolino, A., Clerici, M., \u2026 the REAL-ESK Study Group. Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord. 2023;25(3):233\u201344. https:\/\/doi.org\/10.1111\/bdi.13296.","journal-title":"Bipolar Disord"},{"key":"1606_CR64","doi-asserted-by":"publisher","unstructured":"Nunez NA, Joseph B, Kumar R, Douka I, Miola A, Prokop LJ, \u2026 Singh B. An update on the efficacy of single and serial intravenous ketamine infusions and esketamine for bipolar depression: a systematic review and meta-analysis. Brain Sci. 2023;13(12):1672. https:\/\/doi.org\/10.3390\/brainsci13121672.","DOI":"10.3390\/brainsci13121672"},{"issue":"1","key":"1606_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/02791072.2023.2178558","volume":"56","author":"AG Aguilar","year":"2024","unstructured":"Aguilar AG, Beauregard BA, Conroy CP, Khatiwoda YT, Horsford SME, Nichols SD, Piper BJ. Pronounced regional variation in esketamine and ketamine prescribing to US Medicaid patients. J Psychoactive Drugs. 2024;56(1):33\u20139. https:\/\/doi.org\/10.1080\/02791072.2023.2178558.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"1606_CR66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/PRA.0000000000000766","volume":"30","author":"BS Barnett","year":"2024","unstructured":"Barnett BS. Formulary coverage of esketamine and ketamine for depression in Ohio Health Insurance Marketplace and Medicaid plans. J Psychiatr Pract. 2024;30(2):130\u20133. https:\/\/doi.org\/10.1097\/PRA.0000000000000766.","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"1606_CR67","doi-asserted-by":"publisher","first-page":"e2311250","DOI":"10.1001\/jamanetworkopen.2023.11250","volume":"6","author":"JL Havlik","year":"2023","unstructured":"Havlik JL, Murphy MJ, Gong N, Tang D, Krystal JH. Characteristics of esketamine prescribers among medicare beneficiaries in the United States, 2019\u20132020. JAMA Netw Open. 2023;6(4): e2311250. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.11250.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1606_CR68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40263-022-00907-3","volume":"36","author":"RCJ Bradlow","year":"2022","unstructured":"Bradlow RCJ, Berk M, Kalivas PW, Back SE, Kanaan RA. The Potential of N-Acetyl-L-Cysteine (NAC) in the treatment of psychiatric disorders. CNS Drugs. 2022;36(5):451\u201382. https:\/\/doi.org\/10.1007\/s40263-022-00907-3.","journal-title":"CNS Drugs"},{"key":"1606_CR69","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2147\/CEOR.S413546","volume":"15","author":"A Yenet","year":"2023","unstructured":"Yenet A, Nibret G, Tegegne BA. Challenges to the availability and affordability of essential medicines in African Countries: a scoping review. ClinicoEconomics Outcomes Res. 2023;15:443\u201358. https:\/\/doi.org\/10.2147\/CEOR.S413546.","journal-title":"ClinicoEconomics Outcomes Res"},{"issue":"1","key":"1606_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17. https:\/\/doi.org\/10.1186\/s13643-020-1274-3.","journal-title":"Syst Rev"},{"key":"1606_CR71","doi-asserted-by":"publisher","unstructured":"Abdisa E, Fekadu G, Girma S, Shibiru T, Tilahun T, Mohamed H, \u2026 Tsegaye R. Self-stigma and medication adherence among patients with mental illness treated at Jimma University Medical Center, Southwest Ethiopia. Int J Mental Health Syst. 2020;14(1):56. https:\/\/doi.org\/10.1186\/s13033-020-00391-6.","DOI":"10.1186\/s13033-020-00391-6"},{"key":"1606_CR72","doi-asserted-by":"publisher","unstructured":"Cu\u00e9llar-Barboza AB, McElroy SL, Veldic M, Singh B, Kung S, Romo-Nava F, \u2026 Frye MA. Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. Int J Bipolar Disord. 2020;8(1):23. https:\/\/doi.org\/10.1186\/s40345-020-00184-3.","DOI":"10.1186\/s40345-020-00184-3"},{"key":"1606_CR73","doi-asserted-by":"publisher","unstructured":"Nu\u00f1ez NA, Coombes BJ, Beaupre LM, Ozerdem A, Resendez MG, Romo-Nava F, \u2026 Frye MA. Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorder. Translat Psychiatry. 2024;14(1):93. https:\/\/doi.org\/10.1038\/s41398-024-02798-y.","DOI":"10.1038\/s41398-024-02798-y"},{"issue":"21","key":"1606_CR74","doi-asserted-by":"publisher","first-page":"13485","DOI":"10.3390\/ijms232113485","volume":"23","author":"A Alchakee","year":"2022","unstructured":"Alchakee A, Ahmed M, Eldohaji L, Alhaj H, Saber-Ayad M. Pharmacogenomics in psychiatry practice: the value and the challenges. Int J Mol Sci. 2022;23(21): 13485. https:\/\/doi.org\/10.3390\/ijms232113485.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1606_CR75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41398-022-01928-8","volume":"12","author":"G Sparacino","year":"2022","unstructured":"Sparacino G, Verdolini N, Vieta E, Pacchiarotti I. Existing and emerging pharmacological approaches to the treatment of mania: a critical overview. Transl Psychiatry. 2022;12(1):169. https:\/\/doi.org\/10.1038\/s41398-022-01928-8.","journal-title":"Transl Psychiatry"},{"key":"1606_CR76","doi-asserted-by":"publisher","unstructured":"Kaiser J, Nay K, Horne CR, McAloon LM, Fuller OK, Muller AG, \u2026 Scott JW. CaMKK2 as an emerging treatment target for bipolar disorder. Mol Psychiatry. 2023;28(11):4500\u20134511. https:\/\/doi.org\/10.1038\/s41380-023-02260-3.","DOI":"10.1038\/s41380-023-02260-3"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-025-01606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-025-01606-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-025-01606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:31:13Z","timestamp":1744799473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-025-01606-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s11920-025-01606-8","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"11 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Singh has received research grant support from Mayo Clinic, the National Network of Depression Centers (NNDC), Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2) and NIH. He is a KL2 Mentored Career Development Program scholar, supported by CTSA Grant Number KL2TR002379 from the National Center for Advancing Translational Science (NCATS). Dr. Singh has received honoraria (to institution) from Elsevier for editing a Clinical Overview on Treatment-Resistant Depression. Dr. Yocum declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}